MedTrace Logo

Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate

NCT00041613 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2008-04-01

No results posted yet for this study

Summary

There is a need for more treatment options for patients with recurrent squamous cell cancer of the head and neck (SCCHN). These tumors usually have a variety of genetic defects that include disruption of the p53 pathway, a pathway that would ordinarily work to prevent the development of tumors. In this study the transfer of the p53 gene to tumor cells using a modified adenovirus (INGN 201) will be compared to methotrexate in patients who have failed surgery, radiotherapy and chemotherapy with platinum or taxanes.

Conditions

  • Carcinoma, Squamous Cell

Interventions

GENETIC

INGN 201

Sponsors & Collaborators

  • Introgen Therapeutics

    lead INDUSTRY

Principal Investigators

  • Kerstin Menander, MD

  • Julie L Sicam, MT (ASCP) MSHS

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00041613 on ClinicalTrials.gov